DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis

Information source: Eli Lilly and Company
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoporosis, Postmenopausal

Intervention: Teriparatide (Drug); Raloxifene (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Eli Lilly and Company

Official(s) and/or principal investigator(s):
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study Chair, Affiliation: Eli Lilly and Company


The primary purpose of the study is to compare 3 different osteoporosis therapies following one year of teriparatide. In the first year,all eligible patients received open-label teriparatide 20 micrograms/day. After 1 year, patients are randomly assigned to one of 3 possible follow-up treatment regimens for the second 12 months: continuation of teriparatide, switch to raloxifene, or no pharmacological treatment(other than the calcium and vitamin D supplements that everyone receives). Patients are stratified into 3 subsets: (a) patients who have never received any anti-osteoporosis treatment before; (b) patients who received prior antiresorptive treatment successfully; (c) patients who failed to respond adequately to prior antiresorptive drugs (such as bisphosphonates or raloxifene) in the past. These latter patients are not randomized at month 12 but will continue treatment with teriparatide 20 micrograms/day throughout the second year.

Clinical Details

Official title: Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Lumbar spine BMD after 24 months.

Secondary outcome:

Hip and femoral neck BMD at 24 months.

Comparison of randomized groups, and descriptive analysis of group receiving open-label treatment with teriparatide for 2 years due to prior antiresorptive treatment failure.

Change in itudinal fracture pattern from 3-year pre-study period to end of the study in all patients who receive teriparatide for 2 years.

Change in back pain after 1, 6, 12, and 24 mths.

Safety of teriparatide.


Minimum age: 55 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Ambulatory women greater or equal to 55 years, at least 2 years postmenopausal.

- Lumbar spine or total hip or femoral neck bone mineral density measurement must be at

least 2. 5 standard deviations (SD) below the average bone mass for young women

(T-score - 2. 5 or less).

- Presence of at least one known and documented preexisting clinical fragility

fracture, in the past 3 years. Patients may be included in substudy 2 if they meet any one of the following additional

criteria - Patients who have sustained at least one new fragility fracture (vertebral or

nonvertebral), despite prescription of antiresorptive therapy* during the 12 months prior to the last new fracture or patients who, after a minimum of two years after initiating antiresorptive therapy*, either have a lumbar spine, femoral neck, or total hip BMD of at

least - 3SD below the average bone mass for young women (T-score -3 or less), or who show

a decrease of at least 3. 5% in BMD at any one of these sites. *Antiresorptive therapy includes all bisphosphonates, raloxifene, ERT/HRT, calcitonin, and vitamin D metabolites. Exclusion Criteria: For substudy 1 patients only:

- current or history of vaginal bleeding or spotting of unknown cause in the 1 year

prior to study start

- currently suspected or history of venous thrombotic events (VTE), including lower

extremity thrombosis, and other major venous thromboses, or high risk of developing VTE as assessment by the investigator. Treatment with

- Vitamin D >50,000 IU/week or with any dose of calcitriol or vitamin D analogs or

agonists in the 6 months prior to visit 2

- Fluorides in the 12 months prior to visit 2.

- Systemic corticosteroids (other than for replacement therapy) in the 1 month prior to

visit 2.(Ophthalmic, otic topical, orally inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used without these restrictions.)

Locations and Contacts

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Pyrmont D-31812, Germany
Additional Information

Starting date: August 2002
Last updated: July 12, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017